Conduct a comprehensive 100+ page market report on the pMHC therapeutic space, documenting the development journey (from initial concept through post-market adoption) of all programs progressing to any stage. Focus on Tzield as FDA-approved example and celiac failures, incorporating patient-centered perspective, published PRO data, and PFDD timing across disease areas.

The session aimed to produce a 100+ page market report on the pMHC (peptide-MHC) therapeutic landscape, tracing program development from initial concept through post-market adoption, with Tzield as the FDA-approved case study, celiac program failures, and a patient-centered lens incorporating PRO data and PFDD timing.

The agent compiled a broad set of research notes and data files covering program origins, preclinical work, regulatory history, clinical trials, outcomes, patient-reported outcomes, and post-market activity, then synthesized these into a full landscape report (PDF/HTML) with supporting figures and tables. Discrete workstreams are visible in the file set — trial tracking (trials_master.csv, appendix_trials.md), regulatory/PFDD timing (regulatory.md, pfdd_timeline.md, pfdd_inventory.csv), outcomes and PRO analysis (outcomes_analysis.md, outcomes_matrix.csv, pro_instruments.csv), and patient-voice/EoE-specific material (patient_voice.md, eoe_journey.md, eoe_pipeline.md, eoe_survey_plan.md). Notably, the final agent message defends the report's use of "Teizeild" as a distinct EU trade name for teplizumab separate from the US brand "Tzield" (citing a ~Jan 2026 EU approval) — this claim